|Title||Cardiovascular Inflammation Reduction Trial (CIRT)|
Researchers would like to find out if methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome who have already had at least one heart attack. Methotrexate is a drug commonly used to reduce inflammation (pain and swelling) in the joints of people with rheumatoid arthritis. Rheumatoid arthritis is an inflammatory disease that destroys the joints and can cause serious disabilities. Doctors have noticed that patients taking methotrexate for their arthritis seem to have less of the diseases caused by clogging of the arteries. In this study, we want to find out if giving methotrexate at low doses to people with heart disease will prevent a second heart attack or stroke. This is a randomized, double-blind, placebo-controlled study funded by the National Heart Lung and Blood Institute. Click here for more information.
Adult patients who have had a heart attack in the past 5 years, type 2 diabetes and/or metabolic syndrome are eligible to participate. For more information, visit the Cardiovascular Research site.
|Principal Name||J. Antonio G. Lopez, MD|
|Contact Name||Jamie Duffy, CCRC|
|Current Trial Type||Randomized, double blind, placebo-controlled|